Star Combo Pharma Ltd (ASX: S66) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Star Combo Pharma Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Star Combo Pharma Ltd (ASX: S66)
Latest News
Dividend Investing
16 ASX shares going ex-dividend next week
Dividend Payment History Data provided by Morningstar.
| Ex-Date | Amount | Franking | Type | Payable |
|---|---|---|---|---|
| 14 Oct 2024 | $0.0037 | 100.00% | Final | 31 Oct 2024 |
S66 ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Star Combo Pharma Ltd
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
S66 Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 13 Jan 2026 | $0.26 | $-0.01 | -3.77% | 66 | $0.26 | $0.26 | $0.26 |
| 12 Jan 2026 | $0.27 | $0.01 | 3.85% | 18 | $0.26 | $0.27 | $0.26 |
| 09 Jan 2026 | $0.26 | $0.01 | 4.00% | 11,588 | $0.26 | $0.26 | $0.26 |
| 08 Jan 2026 | $0.25 | $-0.01 | -3.85% | 12,569 | $0.26 | $0.26 | $0.25 |
| 07 Jan 2026 | $0.26 | $0.01 | 4.00% | 35,043 | $0.26 | $0.26 | $0.25 |
| 06 Jan 2026 | $0.25 | $-0.02 | -7.55% | 65,438 | $0.24 | $0.25 | $0.24 |
| 05 Jan 2026 | $0.27 | $0.01 | 3.85% | 51 | $0.27 | $0.27 | $0.27 |
| 02 Jan 2026 | $0.26 | $0.00 | 0.00% | 2,005 | $0.28 | $0.28 | $0.26 |
| 31 Dec 2025 | $0.26 | $-0.01 | -3.70% | 2,889 | $0.27 | $0.27 | $0.26 |
| 30 Dec 2025 | $0.27 | $0.02 | 8.00% | 53,090 | $0.26 | $0.27 | $0.26 |
| 29 Dec 2025 | $0.25 | $0.00 | 0.00% | 57,269 | $0.25 | $0.26 | $0.25 |
| 24 Dec 2025 | $0.25 | $0.01 | 4.17% | 109,395 | $0.24 | $0.25 | $0.24 |
| 23 Dec 2025 | $0.24 | $0.02 | 9.09% | 74,436 | $0.22 | $0.24 | $0.22 |
| 22 Dec 2025 | $0.22 | $0.00 | 0.00% | 40,933 | $0.22 | $0.22 | $0.22 |
| 19 Dec 2025 | $0.22 | $0.00 | 0.00% | 870 | $0.22 | $0.22 | $0.22 |
| 17 Dec 2025 | $0.22 | $0.00 | 0.00% | 65 | $0.22 | $0.22 | $0.22 |
| 16 Dec 2025 | $0.22 | $0.00 | 0.00% | 68 | $0.22 | $0.22 | $0.22 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Richard Ivan Allely | Non-Executive ChairmanNon-Executive Director | Feb 2018 |
Mr Allely has previously held non-executive roles on the boards of Australian Medical Publishing Company Pty Ltd, Perisher Blue Pty Ltd, Australian Property Monitors Pty Ltd and Source Financial Inc. (a USA Public Company). He has also been an independent member of Work Cover Authority of NSW and an advisory board member of Renoir Consulting Group. Richard was the Managing Director and CEO of PMP Ltd (PMP) until 2012, when he stepped down from the position, after serving just over 10 years with the company (seven years as CFO). PMP is the printing and distribution company in Australia and New Zealand with a turnover in excess of $A1 billion. Prior to this, Richard held senior executive roles with a number of Australian and International companies including Tenix Pty Ltd (formerly Transfield Pty Ltd), John Fairfax Holdings Ltd, Boral Ltd, James Hardie Industries Ltd and Fanner-PLP Pty Ltd. Richard has experience in the manufacturing, building and construction, and publication and media sectors within Australia and South East Asia.
|
| Ms Su Zhang | Chief Executive OfficerExecutive Director | Nov 2016 |
Ms Zhang has been working in the pharmaceutical industry for over 10 years, starting her career with Terry White Chemists after graduating from University of Sydney in 2006. Upon leaving Terry White Chemists, Su worked for three years at Abbott Australia. She commenced at Abbott Australia as a Senior Drug Safety Associate and later moved into the role of Asia Pacific Regional Manager. In 2009, Su commenced employment with Star Combo, initially focusing her efforts on obtaining a TGA licence for Costar Pharma. Su's responsibilities within Star Combo include quality control and compliance, operational management, production planning and sales cycle management.
|
| Mr Star (JinXing) Zhang | Managing Director | Nov 2016 |
Mr Zhang is the founder of Star Combo and has a background in the pharmaceutical industry. After graduation from university, Star worked for 10 years at a medical research company in China which produced hard gel capsules, tablets and injections. While there, he pioneered the extraction and purification of hyaluronic acid, important as a lubricant in ocular surgery. Furthermore, he developed methods to separate low molecular weight hyaluronic acid, which is used in cosmetics. Star incorporated Star Combo in 2004 to address the need for Australian-made health foods in the market. Other current directorships include Antoine International Pty Ltd.
|
| Ms Wei Han | Non-Executive Director | May 2020 |
Ms Han, as the Vice Chairman and director of Goldenmax International, has knowledge and experience in company governance of a listed company, compliance and financial management. Prior to joining Goldenmax International, Ms. Han has more than 30 years of experience in company governance and accounting, providing professional services in the Chinese food and consumer industry. Other current directorships include Goldenmax International Technology Ltd.
|
| Mr Jialong Ding | Non-Executive Director | May 2020 |
Mr Ding, as the Vice President of the pharmaceutical business in Goldenmax International, has over 30 years of experience in pharmaceutical distribution, production, and compliance. Prior to this, Mr. Ding held senior executive roles in several Chinese pharmaceutical companies, including subsidiaries of Shanghai Pharma. Mr. Ding was Vice President of China Nonprescription Medicines Association (CNMA) and Vice President of Shanghai Pharmaceutical Profession Association (SPPA).
|
| Mr Patrick Raper | Company Secretary | Oct 2018 |
-
|
| James Ni | Chief Financial Officer |
-
|
|
| Patrick Raper | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Goldenstar Pharmaceutical Investment Limited | 49,000,000 | 36.27% |
| Jinxing(Star) Zhang | 38,165,510 | 28.25% |
| Miss Su Zhang | 11,448,980 | 8.48% |
| Lepu Medical (Europe) Cooperatief U.A. | 11,000,000 | 8.14% |
| Richlink Capital Investments Pty Ltd | 3,541,178 | 2.62% |
| Mr Liang Zuo | 2,243,512 | 1.66% |
| Dw & Rl Pty Ltd | 2,163,335 | 1.60% |
| Mr Jixiang Shi | 2,150,000 | 1.59% |
| Dw & Rl Pty Ltd i | 1,270,934 | 0.94% |
| Icomoon Pty Ltd | 1,246,952 | 0.92% |
| Eureka Technology Innovation & Investment Pty Ltd | 623,000 | 0.46% |
| Paul Thomas Hutchinson | 530,600 | 0.39% |
| Mr Brian Albert Donnelly | 507,658 | 0.38% |
| Thi Uyen Phuong Nguyen | 500,000 | 0.37% |
| Mr Steve Hou | 472,238 | 0.35% |
| Ms Lisha Huang | 455,000 | 0.30% |
| Mrs Aiping Ruan | 402,453 | 0.30% |
| Mr Huilin Lu | 381,681 | 0.28% |
| Miss Jiayi Shi | 356,000 | 0.26% |
| Mr Xing Kang Jin | 349,000 | 0.26% |